184 related articles for article (PubMed ID: 36461940)
1. Oxidative DNA Damage by N4-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir.
Kobayashi H; Mori Y; Ahmed S; Hirao Y; Kato S; Kawanishi S; Murata M; Oikawa S
J Infect Dis; 2023 Apr; 227(9):1068-1072. PubMed ID: 36461940
[TBL] [Abstract][Full Text] [Related]
2. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Yip AJW; Low ZY; Chow VTK; Lal SK
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
[TBL] [Abstract][Full Text] [Related]
3. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
Menéndez-Arias L
J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
[TBL] [Abstract][Full Text] [Related]
4. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
[TBL] [Abstract][Full Text] [Related]
5. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier.
Chang CH; Peng WY; Lee WH; Lin TY; Yang MH; Dalley JW; Tsai TH
EBioMedicine; 2023 Sep; 95():104748. PubMed ID: 37544201
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
[TBL] [Abstract][Full Text] [Related]
7. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
8. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Waters MD; Warren S; Hughes C; Lewis P; Zhang F
Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
[TBL] [Abstract][Full Text] [Related]
9. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
10. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
Zhou S; Hill CS; Sarkar S; Tse LV; Woodburn BMD; Schinazi RF; Sheahan TP; Baric RS; Heise MT; Swanstrom R
J Infect Dis; 2021 Aug; 224(3):415-419. PubMed ID: 33961695
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis.
Kabinger F; Stiller C; Schmitzová J; Dienemann C; Kokic G; Hillen HS; Höbartner C; Cramer P
Nat Struct Mol Biol; 2021 Sep; 28(9):740-746. PubMed ID: 34381216
[TBL] [Abstract][Full Text] [Related]
12. Molnupiravir: an antiviral drug against COVID-19.
Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
[TBL] [Abstract][Full Text] [Related]
13. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses.
Wang Y; Li P; Solanki K; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
Virology; 2021 Dec; 564():33-38. PubMed ID: 34619630
[TBL] [Abstract][Full Text] [Related]
14. The development and validation of a novel LC-MS/MS method for the simultaneous quantification of Molnupiravir and its metabolite ß-d-N4-hydroxycytidine in human plasma and saliva.
Amara A; Penchala SD; Else L; Hale C; FitzGerald R; Walker L; Lyons R; Fletcher T; Khoo S
J Pharm Biomed Anal; 2021 Nov; 206():114356. PubMed ID: 34509661
[TBL] [Abstract][Full Text] [Related]
15. Molnupiravir; molecular and functional descriptors of mitochondrial safety.
Wallace KB; Bjork JA
Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570
[TBL] [Abstract][Full Text] [Related]
16. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance.
Strizki JM; Gaspar JM; Howe JA; Hutchins B; Mohri H; Nair MS; Kinek KC; McKenna P; Goh SL; Murgolo N
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0095323. PubMed ID: 38047645
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of reactive oxygen species generation and oxidative DNA damage induced by acrylohydroxamic acid, a putative metabolite of acrylamide.
Mori Y; Kobayashi H; Fujita Y; Yatagawa M; Kato S; Kawanishi S; Murata M; Oikawa S
Mutat Res Genet Toxicol Environ Mutagen; 2022 Jan; 873():503420. PubMed ID: 35094805
[TBL] [Abstract][Full Text] [Related]
18. The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19).
Pagliano P; Sellitto C; Ascione T; Scarpati G; Folliero V; Piazza O; Franci G; Filippelli A; Conti V
Expert Opin Drug Discov; 2022 Dec; 17(12):1299-1311. PubMed ID: 36508255
[TBL] [Abstract][Full Text] [Related]
19. An active metabolite of the anti-COVID-19 drug molnupiravir impairs mouse preimplantation embryos at clinically relevant concentrations.
Marikawa Y; Alarcon VB
Reprod Toxicol; 2023 Oct; 121():108475. PubMed ID: 37748715
[TBL] [Abstract][Full Text] [Related]
20. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
Bai Y; Shen M; Zhang L
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
